散结镇痛胶囊联合曼月乐治疗子宫腺肌病的Meta分析

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (1199 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the clinical efficacy and safety of San Jie Zhen Tong Capsules combined with Levonorgestrel Intrauterine System in the treatment of adenomyosis. Methods Published papers about randomized controlled trials (RCTs) of San Jie Zhen Tong Capsules combined with Levonorgestrel Intrauterine System in the treatment of adenomyosis from the establishment of the database till December 10, 2017 with language restriction of Chinese and English were searched from various databases, which included PubMed, the Cochrane Library, Web of Science, CBM, Wanfang Data, CNKI, VIP. The subjects were divided into two groups, including Sanjie Zhentong capsules combined with Levonorgestrel Intrauterine System group and mere Levonorgestrel Intrauterine System group. Moreover, the observations including the total efficiency and the indexes of Lesion reduction rate and dysmenorrhea score and endometrial thickness and serum CA125 levels. In addition, a Meta-analysis was conducted with Review Manager 5.3 software. Results Six articles involving 602 patients were included. The Meta-analysis showed that there was a significantly positive effect of San Jie Zhen Tong Capsules combined with Levonorgestrel Intrauterine System in the treatment of adenomyosis. Conclusion San Jie Zhen Tong Capsules combined with Levonorgestrel Intrauterine System can improve not only the indexes of Lesion reduction rate (OR=17.94, 95%CI: [7.47, 43.10], P ＜ 0.000 01), Dysmenorrhea score (MD=-1.72, 95%CI: [-3.37, -0.07], P=0.04), Endometrial thickness (MD =-1.52, 95%CI: [-1.77, -1.27], P ＜ 0.000 01), Serum CA125 levels (MD =-5.74, 95%CI: [-8.12, -3.35], P ＜ 0.000 01), but also the total efficiency (OR=5.38, 95%CI: [3.01, 9.63], P ＜ 0.000 01) and it seems to have no obvious adverse reactions. Conclusion The evidences support that San Jie Zhen Tong Capsules combined with Levonorgestrel Intrauterine System have potential advantages compared to mere Levonorgestrel Intrauterine System therapy in the treatment of adenomyosis.

Key words： San Jie Zhen Tong Capsules Levonorgestrel Intrauterine System Adenomyosis Meta-analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GU Zijuan1 LU Ruling2 YUAN Shuo2 DENG Gaopi2

Cite this article:

GU Zijuan1 LU Ruling2 YUAN Shuo2 DENG Gaopi2. Meta analysis of the efficacy of San Jie Zhen Tong Capsules combined with Levonorgestrel Intrauterine System in treatment of adenomyosis[J]. 中国医药导报, 2018, 15(6): 88-93.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I6/88

[1] 谢幸，苟文丽.妇产科学[M].8版.北京：人民卫生出版社，2013：274-275.
[2] 陈奇，杨丽娟.曼月乐宫内节育器治疗子宫腺肌症近远期临床疗效分析[J].中国妇幼保健，2014，29（8）：1278-1280.
[3] 中国中西医结合学会妇产科专业委员会第三届学术会议修订.子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准[J].中西医结合杂志，1991， 11（6）：376.
[4] 宋楠，王艳艳，冷金花.散结镇痛胶囊对子宫内膜异位症及子宫腺肌病痛经治疗效果观察[J].中国实用妇科与产科杂志，2010,26（3）：222-223.
[5] 张华秀.子宫腺肌病患者放置曼月乐环治疗的护理体会[J].中外健康文摘，2013，7（13）：285-286.
[6] Kim ML，Seong SJ. Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases [J]. Obstet Gynecol Sci，2013，56（2）：67-75.
[7] 徐江群，金敏霞，刘忱.左炔诺孕酮宫内节育系统联合散结镇痛胶囊治疗子宫腺肌症80例[J].中国药师，2014， 17（8）：1350-1352.
[8] 王喜华，焦亦妮.左炔诺孕酮宫内节育系统联合散结镇痛胶囊在子宫腺肌症患者中的应用效果[J].中外医学研究，2016，14（9）：43-45.
[9] 邵永红，王芸.散结镇痛胶囊联合曼月乐治疗子宫腺肌病临床效果及安全性评价[J].实用药物与临床，2013，16（11）：1038-1041.
[10] 马幼菊，马晓莉.散结镇痛胶囊联合曼月乐治疗子宫腺肌病疗效观察[J].医学研究与教育，2014，31（4）：16-19.
[11] 陶艳玲，徐鑫，甄学慧.曼月乐联合散结镇痛胶囊治疗子宫腺肌病的临床评价[J].中国妇幼保健，2013，28（19）：3204-3206.
[12] 岳倩，江楠，支云清，等.LNG-IUS联合药物治疗子宫腺肌病的临床效果[J].齐鲁医学杂志，2014，29（2）：132-136.
[13] Jadad AR，Moore RA，Carroll D，et al. Assessing the quality of reports of randomized clinical trials：is blinding necessary？ [J]. Control Clinical Trials,1996,17（1）：1-12.
[14] Cochrane Handbook for Systematic Reviews of Intenreventions Version 5.0.1（updated September 2008）[D].The Cochrane Collaboration,2008.Accessed 10 March 2009.
[15] 张莉嘉，翁梨驹.左炔诺孕酮宫内系统临床使用五年的安全性研究[J].中华妇产科杂志，2001，36（11）：675-677.
[16] 中国中西医结合学会妇产科专业委员会第三届学术会议修订.子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准[J].中西医结合杂志，1991， 11（6）：376.
[17] 司徒仪，沈碧琼.子宫内膜异位症瘀证本质及活血化瘀疗效机理探讨[J].北京中医，1998（3）：11-13.
[18] 赵良倩，王荣幸.消痛合剂对子宫内膜异位症大鼠血浆PGE2、6keto、PGFla水平的影响[J].中国医药指南，2008， 6（4）：4-6.
[19] 刘素玲，杨敏.补肾活血药对子宫内膜异位大鼠腹腔液的影响[J].医药论坛杂志，2007，28（2）：46-47.
[20] 周华，齐聪.补肾活血法对子宫内膜异位症模型大鼠细胞凋亡的影响[J].中医杂志，2009，50（2）：165-168.
[21] 周艳艳.补肾活血法对EMs大鼠模型细胞因子的影响[J].河南中医学院学报，2008，134（23）：35-36.
[22] 杨新园，颉小侠.中药治疗后MMP-9、TIMP-1及CA125在异位和在位子宫内膜中的表达[J].西安交通大学学报（医学版），2009，30（6）：762-765.